DDInter336 DDInter286
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Celecoxib {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ticlopidine
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Celecoxib {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Celecoxib {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Celecoxib {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Celecoxib {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Meloxicam
Meloxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caplacizumab
Celecoxib {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Caplacizumab
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Celecoxib (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ticlopidine (Compound) and Ticlopidine may lead to a major life threatening interaction when taken with Caplacizumab
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound) and Ponatinib may lead to a major life threatening interaction when taken with Caplacizumab
Celecoxib (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Celecoxib (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Caplacizumab
Celecoxib (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Caplacizumab
Celecoxib (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Celecoxib (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab